Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.

Mary-Ellen Taplin,Franklin Chu,James S. Cochran,Karen J. Ferrante,David Uri Lipsitz,Jennifer Roberts,Oliver Sartor,Elisabeth I. Heath

Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.

2016

Mary-Ellen Taplin
Franklin Chu
James S. Cochran
Karen J. Ferrante
David Uri Lipsitz
Jennifer Roberts
Oliver Sartor
Elisabeth I. Heath

5064Background: Galeterone is an oral small molecule that disrupts androgen receptor (AR) signaling via multiple pathways: AR degradation, CYP17 inhibition, and AR antagonism. Immunofluorescent sta...

Keywords:

Androgen receptor
Galeterone
Prostate cancer
Castration
Pathology
Cancer research
Medicine
Antagonism
therapy naive
castration resistant
Small molecule

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations